Martine Zimmermann
Direttore/Membro del Consiglio presso INVENTIVA
Patrimonio netto: 300 822 $ in data 31/05/2024
Posizioni attive di Martine Zimmermann
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| INVENTIVA | Direttore/Membro del Consiglio | 16/04/2021 | - |
| Independent Dir/Board Member | 16/04/2021 | - | |
| LIGAND PHARMACEUTICALS INCORPORATED | Direttore/Membro del Consiglio | 26/09/2023 | - |
| Independent Dir/Board Member | 26/09/2023 | - | |
| Ipsen Biopharmaceuticals, Inc. | Consigliere Generale | - | - |
Storia della carriera di Martine Zimmermann
Precedenti posizioni note di Martine Zimmermann
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Consigliere Generale | 01/06/2016 | 01/02/2023 |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Direttore/Membro del Consiglio | 01/03/2019 | 01/01/2021 |
Formazione di Martine Zimmermann
| Louis Pasteur University | Doctorate Degree |
| University of Strasbourg | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| Francia | 4 |
Posizioni
| Director/Board Member | 3 |
| Independent Dir/Board Member | 2 |
| General Counsel | 2 |
Settori
| Health Technology | 5 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| INVENTIVA | Health Technology |
| LIGAND PHARMACEUTICALS INCORPORATED | Health Technology |
| Aziende private | 3 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Caelum Biosciences, Inc. operates as a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. The company was founded in January 2017 and is headquartered in New York, NY. | Health Technology |
| Ipsen Biopharmaceuticals, Inc. |
- Borsa valori
- Insiders
- Martine Zimmermann
- Esperienza
